These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group. Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497 [No Abstract] [Full Text] [Related]
3. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Löwenberg B Blood; 2013 Jan; 121(1):26-8. PubMed ID: 23287624 [TBL] [Abstract][Full Text] [Related]
4. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Yin B; Tsai ML; Hasz DE; Rathe SK; Le Beau MM; Largaespada DA Leukemia; 2007 May; 21(5):1093-7. PubMed ID: 17301810 [No Abstract] [Full Text] [Related]
5. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736 [No Abstract] [Full Text] [Related]
6. Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia. Ramakrishnan R; Munir F; Quesada AE; Hitzler J; Cuglievan B Pediatr Blood Cancer; 2024 Jun; 71(6):e30974. PubMed ID: 38523255 [No Abstract] [Full Text] [Related]
7. Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients. Hengge UR; Schultewolter T; Uppenkamp T AIDS; 1998 Jan; 12(2):221-2. PubMed ID: 9468375 [No Abstract] [Full Text] [Related]
8. Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. Walter RB; Appelbaum FR; Estey EH Leukemia; 2021 Feb; 35(2):295-298. PubMed ID: 33328603 [No Abstract] [Full Text] [Related]
14. [Observation and care in high-dose cytarabine treatment of acute myelogenous leukemia]. Xi YR; Tu YL; Zhao XH Zhonghua Hu Li Za Zhi; 1996 Nov; 31(11):653-5. PubMed ID: 9304928 [No Abstract] [Full Text] [Related]
15. Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. Song JH; Cho KM; Kim HJ; Kim YK; Kim NY; Kim HJ; Lee TH; Hwang SY; Kim TS Oncol Rep; 2015 Jul; 34(1):488-94. PubMed ID: 25955569 [TBL] [Abstract][Full Text] [Related]
16. [Petechiae, suffusions and cytarabine-induced erythema in treatment of acute myeloid leukemia]. Taverna C; Jacky E; Sauter C Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1117. PubMed ID: 9691347 [No Abstract] [Full Text] [Related]
17. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia. Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of cytarabine in childhood leukemia. Lamba JK Pharmacogenomics; 2011 Dec; 12(12):1629-32. PubMed ID: 22118048 [No Abstract] [Full Text] [Related]
19. Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia? Appelbaum FR Nat Rev Clin Oncol; 2010 Nov; 7(11):619-21. PubMed ID: 20981126 [No Abstract] [Full Text] [Related]
20. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]